InSphero Strengthens Scientific Advisory Board To Advance Drug Discovery and Safety Solutions

InSphero AG, today announced the strengthening of its Scientific Advisory Board (SAB) with the appointment of Professors Thomas Hartung, MD PhD, Matthias von Herrath, MD, and Gerd Kullak-Ublick, MD.

“We are pleased to welcome these distinguished researchers to our SAB,” says InSphero CEO and co-founder Jan Lichtenberg, PhD. “They are all leading experts in their respective fields and will provide invaluable insights as we continue to advance our tailored drug development efforts at the forefront of preclinical research, with an emphasis on metabolic diseases, diabetes, oncology, and safety programs.” Prof. Hartung is a Professor of Evidence-based Toxicology and Director of the Center for Alternatives to Animal Testing at Johns Hopkins University, and Professor of Pharmacology and Toxicology at the University of Konstanz. He is a passionate advocate for replacing animal testing with more ethical and predictive in vitro models and is investigating new applications for big data and artificial intelligence in toxicity testing. Prof. von Herrath holds a dual appointment as Vice President and Senior Medical Officer at Novo Nordisk and Professor at the La Jolla Institute for Immunology Center for Autoimmunity and Inflammation. One of the world’s leading type 1 diabetes researchers, he is committed to clinical translation of immune-based interventions in autoimmune and metabolic diseases. Prof. Kullak-Ublick is a Full Professor and Director of the Department of Clinical Pharmacology and Toxicology at the University Hospital Zurich. His primary research interests include function and regulation of drug transporters, new biomarkers of drug safety, and drug-induced liver and kidney injury. Prof. Kullak-Ublick’s contributions in the fields of pharmacology, toxicology, gastroenterology, and hepatology have received critical acclaim and recognition from honorable subject experts around the world.

InSphero Chief Scientific Officer, Prof. Armin Wolf, PhD, who looks forward to engaging and productive discussions with these new SAB members, says, “Visionary science has always been a driving force for InSphero innovation in drug discovery and safety. Our SAB will not only guide us, but also serve as a sparring partner to challenge us and bring added value to our collaborative research partnerships with leading pharma and biotech organizations.”